The Assistance Fund is now providing financial assistance to help patients living with Gaucher disease (GD).
The new fund will provide GD patients and families with financial aid for copayments, coinsurance, deductibles, health insurance premiums and incidental medical expenses related to their disease.
“Gaucher disease is a rare and complex genetic disease with significant and varied symptoms that often require management by a multidisciplinary team of healthcare professionals,” Mark P. McGreevy, president of The Assistance Fund, said in a press release. “We are pleased to be able to provide financial assistance for adults and children with Gaucher disease with the opening of the broadest fund that we have available, covering copays, insurance premiums and incidental medical expenses for those who qualify for our programs,” he said.
The Assistance Fund is a non-profit organization focused on helping patients and families that have high medical-related costs. The foundation provides financial assistance for their copayments, coinsurance, deductibles and other health-related expenses. Each of the 30 funds that the foundation currently manages cover drugs approved by FDA to treat a specific disease.
Through the new fund, patients and families facing financial problems due to GD will be covered for all medications approved by the U.S. Food and Drug Administration (FDA) to treat this challenging disease.
More information about the foundation, the available funds, and eligibility criteria can be found by visiting the website at tafcares.org, or be calling (844) 294-6406 to speak with a patient advocate.
Since the Assistance Fund can open and close new funds at any time, allocating them to patients in need of assistance, the foundation strongly advises those in need to be checking its website regularly.
Gaucher disease (GD) is a genetic disorder in which glucocerebroside (a lipid, also known as glucosylceramide) accumulates in cells and certain organs. The disorder is characterized by bruising, fatigue, anemia, low blood platelet count and enlargement of the liver and spleen. Depending on the type of disease, GD also can lead to lung disease, and bone abnormalities, as well as problems in the central nervous system or cardiovascular system. The disease occurs in one in 50,000 to 100,000 people in the general population.